Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life

SEER stat fact sheets: thyroid cancer. Surveillance, epidemiology, and end results program. http://seer.cancer.gov/statfacts/html/thyro.html [accessed 22.03.17]. Elisei, 2010, Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question, J Clin Endocrinol Metab, 95, 1516, 10.1210/jc.2009-1536 Durante, 2006, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy, J Clin Endocrinol Metab, 91, 2892, 10.1210/jc.2005-2838 Kwong, 2014, Long-term, treatment-free survival in select patients with distant metastatic papillary thyroid cancer, Endocr Connect, 3, 207, 10.1530/EC-14-0097 De Besi, 1991, Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer, J Endocrinol Invest, 14, 475, 10.1007/BF03346846 Bible, 2016, Evolving molecularly targeted therapies for advanced-stage thyroid cancers, Nat Rev Clin Oncol, 13, 403, 10.1038/nrclinonc.2016.19 Druker, 2001, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia, N Engl J Med, 344, 1031, 10.1056/NEJM200104053441401 Posner, 1994, Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program, Mol Pharmacol, 45, 673 Gotink, 2010, Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?, Angiogenesis, 13, 1, 10.1007/s10456-009-9160-6 Lin, 2012, Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy, PLoS ONE, 7, e46726, 10.1371/journal.pone.0046726 Fagin, 2008, Molecular pathology of thyroid cancer: diagnostic and clinical implications, Best Pract Res Clin Endocrinol Metab, 22, 955, 10.1016/j.beem.2008.09.017 Elisei, 2012, Advances in the follow-up of differentiated or medullary thyroid cancer, Nat Rev Endocrinol, 8, 466, 10.1038/nrendo.2012.38 Cancer Genome Atlas Research Network, 2014, Integrated genomic characterization of papillary thyroid carcinoma, Cell, 159, 676, 10.1016/j.cell.2014.09.050 Lodish, 2000, Cancer Romei, 2016, A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma, Nat Rev Endocrinol, 12, 192, 10.1038/nrendo.2016.11 Santoro, 2000, Gene rearrangement and Chernobyl related thyroid cancers, Br J Cancer, 82, 315, 10.1054/bjoc.1999.0921 Elisei, 2001, RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults, J Clin Endocrinol Metab, 86, 3211 Romei, 2012, RET/PTC translocations and clinico-pathological features in human papillary thyroid carcinoma, Front Endocrinol, 3, 54, 10.3389/fendo.2012.00054 Yoo, 2016, Comprehensive analysis of the transcriptional and mutational landscape of follicular and papillary thyroid cancers, PLoS Genet, 12, e1006239, 10.1371/journal.pgen.1006239 Kroll, 2000, PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected], Science, 289, 1357, 10.1126/science.289.5483.1357 Jayson, 2016, Antiangiogenic therapy in oncology: current status and future directions, Lancet, 388, 518, 10.1016/S0140-6736(15)01088-0 Nersita, 2012, Decreased serum vascular endothelial growth factor-D levels in metastatic patients with differentiated thyroid carcinoma, Clin Endocrinol, 76, 142, 10.1111/j.1365-2265.2011.04183.x De Falco, 2002, Structure and function of placental growth factor, Trends Cardiovasc Med, 12, 241, 10.1016/S1050-1738(02)00168-8 Shibuya, 2008, Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis, BMB Rep, 41, 278, 10.5483/BMBRep.2008.41.4.278 Albuquerque, 2013, The newest member of the VEGF family, Blood, 121, 4015, 10.1182/blood-2013-03-490367 Karaca, 2011, VEGFR1 expression is related to lymph node metastasis and serum VEGF may be a marker of progression in the follow-up of patients with differentiated thyroid carcinoma, Eur J Endocrinol/Eur Fed Endocr Soc, 164, 277, 10.1530/EJE-10-0967 Yasuoka, 2005, VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma, Mod Pathol, 18, 1127, 10.1038/modpathol.3800402 Inai, 2004, Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts, Am J Pathol, 165, 35, 10.1016/S0002-9440(10)63273-7 Kamba, 2006, VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature, Am J Physiol Heart Circ Physiol, 290, H560, 10.1152/ajpheart.00133.2005 Baffert, 2006, Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling, Am J Physiol Heart Circ Physiol, 290, H547, 10.1152/ajpheart.00616.2005 Mancuso, 2006, Rapid vascular regrowth in tumors after reversal of VEGF inhibition, J Clin Invest, 116, 2610, 10.1172/JCI24612 Forsythe, 1996, Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1, Mol Cell Biol, 16, 4604, 10.1128/MCB.16.9.4604 Burrows, 2010, Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas, Endocr Relat Cancer, 17, 61, 10.1677/ERC-08-0251 Zerilli, 2010, BRAF(V600E) mutation influences hypoxia-inducible factor-1 alpha expression levels in papillary thyroid cancer, Mod Pathol, 23, 1052, 10.1038/modpathol.2010.86 Papotti, 2000, Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid, Endocr Pathol, 11, 19, 10.1385/EP:11:1:19 Ramirez, 2000, Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma, Clin Endocrinol (Oxf), 53, 635, 10.1046/j.1365-2265.2000.01124.x Rong, 1994, Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation, Proc Natl Acad Sci U. S A, 91, 4731, 10.1073/pnas.91.11.4731 Scarpino, 2004, Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid, J Pathol, 202, 352, 10.1002/path.1522 Xie, 2012, Sorafenib for treatment of hepatocellular carcinoma: a systematic review, Dig Dis Sci, 57, 1122, 10.1007/s10620-012-2136-1 Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655 Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857 Gupta-Abramson, 2008, Phase II trial of sorafenib in advanced thyroid cancer, J Clin Oncol Off J Am Soc Clin Oncol, 26, 4714, 10.1200/JCO.2008.16.3279 Kloos, 2009, Phase II trial of sorafenib in metastatic thyroid cancer, J Clin Oncol Off J Am Soc Clin Oncol, 27, 1675, 10.1200/JCO.2008.18.2717 Brose, 2014, Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial, Lancet, 384, 319, 10.1016/S0140-6736(14)60421-9 Brose, 2016, Sequencing of tyrosine kinase inhibitors in progressive differentiated thyroid cancer, Clin Adv Hematol Oncol H&O, 14, 7 Schlumberger, 2014, Exploratory analysis of outcomes for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-RDTC) receiving open-label sorafenib post-progression on the phase III DECISION trial Nakazawa, 2015, Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model, Cancer Sci, 106, 201, 10.1111/cas.12581 Cabanillas, 2015, A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment, Cancer, 121, 2749, 10.1002/cncr.29395 Schlumberger, 2015, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer, N Engl J Med, 372, 621, 10.1056/NEJMoa1406470 Habra, 2015, Outcomes by site of metastasis for patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib versus placebo: results from a phase 3, randomized trial Brose, 2015, Lenvatinib and the effect of age on overall survival for patients with radioiodine-refractory differentiated thyroid cancer Elisei, 2015, Subgroup analysis according to differentiated thyroid cancer histology in phase 3 (SELECT) trial of lenvatinib, Oncol Res Treat 2015, 38, 1 Schlumberger, 2014, Definition and management of radioactive iodine-refractory differentiated thyroid cancer, Lancet Diabetes Endocrinol, 2, 356, 10.1016/S2213-8587(13)70215-8 Miyauchi, 2011, Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy, Thyroid, 21, 707, 10.1089/thy.2010.0355 Giraudet, 2007, Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels, J Clin Endocrinol Metab, 92, 4185, 10.1210/jc.2007-1211 Robbins, 2006, Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning, J Clin Endocrinol Metab, 91, 498, 10.1210/jc.2005-1534 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Cabanillas, 2012, Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma, Endocr-Relat Cancer, 19, C19, 10.1530/ERC-11-0371 Deandreis, 2011, Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?, Endocr-Relat Cancer, 18, 159, 10.1677/ERC-10-0233 Tuttle, 2016, Best use of the tyrosine kinase inhibitors in progressive differentiated thyroid cancer: discussion, Clin Adv Hematol Oncol H&O, 14, 12 Bonichon, 2015, Local treatment of metastases from differentiated thyroid cancer, Ann d'endocrinol, 76, S40 Dupuy, 2001, Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy, Surgery, 130, 971, 10.1067/msy.2001.118708 Eustatia-Rutten, 2003, Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma, J Clin Endocrinol Metab, 88, 3184, 10.1210/jc.2003-030231 Lewis, 2002, Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma, Am J Roentgenol, 178, 699, 10.2214/ajr.178.3.1780699 Oken, 1982, Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, 5, 649, 10.1097/00000421-198212000-00014 Valerio, 2017, Targeted therapy in thyroid cancer: state of the art, Clin Oncol R Coll Radiol, 29, 316, 10.1016/j.clon.2017.02.009 Lamartina, 2016, Antiangiogenic tyrosine kinase inhibitors: occurrence and risk factors of hemoptysis in refractory thyroid cancer, J Clin Endocrinol Metab, 101, 2733, 10.1210/jc.2015-4391 Worden, 2015, Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer, Endocr-Relat Cancer, 22, 877, 10.1530/ERC-15-0252 Abdulrahman, 2010, Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination, J Clin Endocrinol Metab, 95, 3758, 10.1210/jc.2009-2507 2010 Sherman, 2008, Motesanib diphosphate in progressive differentiated thyroid cancer, N Engl J Med, 359, 31, 10.1056/NEJMoa075853 Locati, 2014, Treatment of advanced thyroid cancer with axitinib: phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments, Cancer, 120, 2694, 10.1002/cncr.28766 Brose, 2016, Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial, Lancet Oncol, 17, 1272, 10.1016/S1470-2045(16)30166-8 Cappagli, 2014, Metastatic thyroid cancer unresponsive to conventional therapy treated with sorafenib “Off-Label”: an update of our 6 years of experience, Eur Thyroid J, 103